Lexeo Therapeutics (LXEO) Competitors $4.22 +0.20 (+4.98%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$4.42 +0.20 (+4.76%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. BCYC, MGTX, BCAX, KURA, DNA, ATAI, ZVRA, TYRA, MAZE, and VALNShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Bicycle Therapeutics (BCYC), MeiraGTx (MGTX), Bicara Therapeutics (BCAX), Kura Oncology (KURA), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Maze Therapeutics (MAZE), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Its Competitors Bicycle Therapeutics MeiraGTx Bicara Therapeutics Kura Oncology Ginkgo Bioworks atai Life Sciences Zevra Therapeutics Tyra Biosciences Maze Therapeutics Valneva Lexeo Therapeutics (NASDAQ:LXEO) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Does the media favor LXEO or BCYC? In the previous week, Lexeo Therapeutics and Lexeo Therapeutics both had 1 articles in the media. Bicycle Therapeutics' average media sentiment score of 0.94 beat Lexeo Therapeutics' score of 0.89 indicating that Bicycle Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lexeo Therapeutics Positive Bicycle Therapeutics Positive Is LXEO or BCYC more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -790.07%. Bicycle Therapeutics' return on equity of -25.54% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -85.86% -68.48% Bicycle Therapeutics -790.07%-25.54%-21.23% Which has better valuation & earnings, LXEO or BCYC? Lexeo Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K215.54-$98.33M-$3.30-1.28Bicycle Therapeutics$35.28M13.80-$169.03M-$3.14-2.24 Do analysts recommend LXEO or BCYC? Lexeo Therapeutics currently has a consensus target price of $16.60, indicating a potential upside of 293.36%. Bicycle Therapeutics has a consensus target price of $25.00, indicating a potential upside of 255.62%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Bicycle Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Do insiders & institutionals believe in LXEO or BCYC? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, LXEO or BCYC? Lexeo Therapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. SummaryBicycle Therapeutics beats Lexeo Therapeutics on 9 of the 15 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$133.45M$2.43B$5.48B$8.94BDividend YieldN/A1.79%5.38%4.12%P/E Ratio-1.288.7826.2219.74Price / Sales215.54636.32405.42109.12Price / CashN/A154.3736.4957.06Price / Book1.204.467.945.37Net Income-$98.33M$31.16M$3.15B$248.34M7 Day Performance0.72%0.38%0.77%1.67%1 Month Performance55.15%8.14%3.47%4.56%1 Year Performance-69.90%3.02%34.86%18.42% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.1328 of 5 stars$4.22+5.0%$16.60+293.4%-73.0%$133.45M$650K-1.2858BCYCBicycle Therapeutics3.7968 of 5 stars$7.23-2.6%$25.00+245.8%-65.4%$513.86M$35.28M-2.30240MGTXMeiraGTx4.4399 of 5 stars$6.31-0.5%$24.00+280.3%+58.0%$509.52M$33.28M-2.72300News CoveragePositive NewsBCAXBicara TherapeuticsN/A$9.18-1.5%$31.86+247.0%N/A$508.28MN/A0.0032KURAKura Oncology4.5424 of 5 stars$5.87+0.3%$24.50+317.4%-73.6%$506.46M$53.88M-2.80130DNAGinkgo Bioworks0.819 of 5 stars$8.55-0.2%$5.77-32.6%N/A$501.62M$227.04M-0.93640Gap DownATAIatai Life Sciences3.0139 of 5 stars$2.02-18.5%$8.67+329.0%+100.7%$496.84M$310K-2.2280Trending NewsOptions VolumeGap UpHigh Trading VolumeZVRAZevra Therapeutics2.7225 of 5 stars$9.00-0.4%$22.29+147.6%+98.4%$494.30M$23.61M-4.7420Positive NewsTYRATyra Biosciences1.9887 of 5 stars$9.71+5.2%$30.83+217.5%-43.8%$490.02MN/A-5.9620News CoverageAnalyst ForecastMAZEMaze TherapeuticsN/A$10.73-4.0%$25.67+139.2%N/A$489.65M$167.50M0.00121VALNValneva2.0091 of 5 stars$5.56-1.1%$15.50+178.8%-19.0%$478.23M$183.52M-4.67700Gap Up Related Companies and Tools Related Companies Bicycle Therapeutics Competitors MeiraGTx Competitors Bicara Therapeutics Competitors Kura Oncology Competitors Ginkgo Bioworks Competitors atai Life Sciences Competitors Zevra Therapeutics Competitors Tyra Biosciences Competitors Maze Therapeutics Competitors Valneva Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXEO Stock Alerts